NASDAQ:MDWDMediwound Stock Price, Forecast & News

Mediwound's stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MDWD shares have increased by 45.9% and is now trading at $3.37. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mediwound.

Mediwound is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Mediwound.

Mediwound Ltd (NASDAQ:MDWD) announced its quarterly earnings results on Wednesday, May, 20th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The biopharmaceutical company had revenue of $4.44 million for the quarter, compared to the consensus estimate of $4.25 million. Mediwound had a negative return on equity of 75.91% and a net margin of 18.46%. View Mediwound's earnings history.

2 equities research analysts have issued 1 year price targets for Mediwound's stock. Their forecasts range from $5.50 to $7.00. On average, they anticipate Mediwound's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 85.5% from the stock's current price. View analysts' price targets for Mediwound.

Headlines about MDWD stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mediwound earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Mediwound.

Mediwound saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 47,100 shares, an increase of 57.0% from the May 31st total of 30,000 shares. Based on an average daily volume of 97,200 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.3% of the company's stock are sold short. View Mediwound's Current Options Chain.

Some companies that are related to Mediwound include Chromadex (CDXC), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE), Beleave (BE) and Rock Creek Pharmaceuticals (RCPIQ). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Mastercard (MA), Wells Fargo & Co (WFC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sorrento Therapeutics (SRNE), Alibaba Group (BABA) and Chubb (CB).

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

Mediwound's stock is owned by many different retail and institutional investors. Top institutional investors include Thomasville National Bank (0.08%).

MDWD stock was acquired by a variety of institutional investors in the last quarter, including Thomasville National Bank.

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MDWD stock can currently be purchased for approximately $3.37.

Mediwound has a market capitalization of $91.66 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis. Mediwound employs 73 workers across the globe.

The official website for Mediwound is www.mediwound.com.

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]